Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRAFree Report) in a report released on Wednesday morning, Benzinga reports. The firm currently has a $15.00 price target on the stock.

Several other research firms have also weighed in on ZVRA. Cantor Fitzgerald reiterated an overweight rating on shares of Zevra Therapeutics in a research note on Monday. William Blair restated an outperform rating on shares of Zevra Therapeutics in a research report on Tuesday, March 12th. Finally, Maxim Group increased their price target on Zevra Therapeutics from $12.00 to $18.00 and gave the stock a buy rating in a research report on Tuesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus price target of $19.50.

View Our Latest Analysis on Zevra Therapeutics

Zevra Therapeutics Trading Down 1.7 %

ZVRA stock opened at $5.03 on Wednesday. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $7.28. The firm has a market cap of $182.18 million, a P/E ratio of -3.90 and a beta of 1.81. The business’s 50 day moving average is $6.13 and its 200-day moving average is $5.38. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.65.

Institutional Investors Weigh In On Zevra Therapeutics

A number of large investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio grew its position in Zevra Therapeutics by 52.5% during the 4th quarter. Public Employees Retirement System of Ohio now owns 5,337 shares of the company’s stock worth $35,000 after acquiring an additional 1,837 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Zevra Therapeutics by 17.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 35,703 shares of the company’s stock worth $234,000 after buying an additional 5,337 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Zevra Therapeutics by 134.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock worth $63,000 after buying an additional 5,545 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in Zevra Therapeutics by 555.0% during the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock worth $43,000 after buying an additional 5,550 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Zevra Therapeutics by 6.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 96,130 shares of the company’s stock worth $630,000 after buying an additional 5,698 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Recommended Stories

Analyst Recommendations for Zevra Therapeutics (NASDAQ:ZVRA)

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.